Non-profit organization committed to improvement and dissemination of knowledge regarding the pathology and pathophysiology of renal disease

Efficacy and Safety of Atacicept in IgA Nephropathy

This study will evaluate the safety, tolerability, dose response and efficacy of atacicept in patients with IgA nephropathy and persistent proteinuria. The study hypothesis is that treatment with atacicept will reduce proteinuria compared to the placebo.

Click here to learn more!

A Phase 2 Study to Evaluate the Safety and Biologic Activity of APL- 2 in Patients With IgA Nephropathy, Lupus Nephritis, Primary Membranous Nephropathy, or C3 Glomerulopathy

This Phase II clinical trial assess the safety and preliminary efficacy of daily APL-2 subcutaneous infusions administered in patients with glomerulopathies between the ages of 18 to 69.

Click here to learn more!

Hydroxychloroquine Sulfate Alleviates Persistent Proteinuria in IgA Nephropathy (HCQIgAN)

This trial will study how hydroxychloroquine can affect IgAN patients by possible reducing or eliminating proteinuria. Previous studies have found that hydroxychloroquine can aid in renal remission and delay renal damage in patients with lupus nephritis. Hydroxychloroquine is an antimalarial agent and is able to affect immune activation by reducing many of the cells that play a factor in abnormal mucosal response, or deviant biological responses on the surfaces of the kidney exposed to the environment. Given the known abilities of hydroxychloroquine, it’s effects on IgAN patients will be studied.

Click here to learn more!

Efficacy and Safety of Abelmoschus Manihot for IgA Nephropathy

The purpose of this study is to evaluate the safety and efficacy of Abelmoschus manihot for treating IgA nephropathy in large scale samples with long time take. IgA nephropathy is the most common primary glomerular disease in China. Huangkui Capsule is a single medicament of traditional Chinese medicine consists of Abelmoschus manihot and has been widely used to treat kidney disease.

Click here for more!